We recently published a list of 10 Stocks Under $10 that Will Triple. In this article, we are going to take a look at where ...

Truist analyst Joon Lee lowered the firm’s price target on Arvinas (ARVN) to $21 from $65 and keeps a Buy rating on the shares as part of a ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Argenx Se (ARGX – Research Report), Roche Holding (RHHBY – ...

HC Wainwright restated their buy rating on shares of Arvinas (NASDAQ:ARVN – Free Report) in a research report report published on Monday morning,Benzinga reports. They currently have a $81.00 price ...

Arvinas, Inc. (NASDAQ:ARVN – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the fifteen brokerages that are currently covering the company, MarketBeat reports. Five ...

Arvinas is continuing its investigation of arv-102 in neurodegenerative diseases associated with lrrk2 and lysosome ...

Arvinas, Inc. (NASDAQ:ARVN) unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ...

The Phase I trial saw repeated oral doses of ARV-102 able to more than half the protein suspected to play a factor in ...

Arvinas reported early-stage data for its PROTAC program in healthy volunteers, hoping the results will eventually translate ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

According to TipRanks.com, Risinger is a 5-star analyst with an average return of 8.5% and a 54.1% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Structure ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...